Search - tctmd.com

Displaying 1 - 20 of 92

Sort: Relevancy | Date

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Daily News

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

L.A. McKeown

July 15, 2025

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

L.A. McKeown

April 24, 2025

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

L.A. McKeown

April 23, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

L.A. McKeown

July 01, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Opinion CV Team Dispatch

March 2024 Dispatch for the CV Team

L.A. McKeown

March 01, 2024

News Conference News ISET 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

Caitlin E. Cox

January 24, 2024

News Daily News

New Scientific Statement Focuses on Below-the-Knee Technical Challenges

L.A. McKeown

January 19, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

L.A. McKeown

September 12, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

Advertisement

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

POPCORN: Hemodialysis Patients Fare Well With Tailored PAD Therapies

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

Top Endovascular News of 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

July 2024 Dispatch for the CV Team

FDA Approves Bioresorbable Scaffold for BTK Lesions

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

March 2024 Dispatch for the CV Team

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

New Scientific Statement Focuses on Below-the-Knee Technical Challenges

Top Endovascular News of 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 2023 News Roundup

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content